文献速递类风湿关节炎

类风湿关节炎生物制剂与JAK抑制剂治疗顺序及治疗线数:对新型药物和预测性生物标志物诊断设计与 uptake 的启示

Treatment Sequencing and Line of Therapy for Biologics and JAK Inhibitors in Patients With Rheumatoid Arthritis: Implications for Design and Uptake of New Drugs and Predictive Biomarker Diagnostics.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-06-02

该研究基于美国健康计划索赔数据库构建的类风湿关节炎(RA)起始队列,分析了RA治疗顺序及生物制剂/JAK抑制剂(JAKi)的启动情况,并按治疗线数(LoT)分层。在37,656例RA患者中识别出59,557次新RA治疗启动,其中85.2%启动生物制剂,其余启动JAKi;40.2%以生物制剂/JAKi单药治疗。总体生物制剂/JAKi添加/换用率为每100患者年25.7次(生物制剂初治患者22.7/100 py,经治患者>30/100 py),且不同处方者间差异显著(最高十分位53.8/100 py vs 最低十分位12.1/100 py)。

要点

  • 多数RA患者启动生物制剂而非JAKi,且四成以生物制剂/JAKi单药治疗。
  • 生物制剂/JAKi添加/换用率在经治患者中高于初治患者。
  • 不同处方者间添加/换用率差异超过四倍,提示实践模式异质性。

核心结论

  • 研究揭示了美国每年启动新型RA生物制剂或JAKi治疗的合格RA患者人群的规模与特征,为开发或营销新RA疗法及预测治疗反应的生物标志物诊断测试的各方提供了有价值的见解。

研究设计与样本

  • 基于美国健康计划索赔数据库构建的RA起始队列研究,共纳入37,656例RA患者,识别59,557次新RA治疗启动。

主要发现

  • 85.2%的新RA治疗启动为生物制剂,其余为JAKi;40.2%以生物制剂/JAKi单药治疗。
  • 总体生物制剂/JAKi添加/换用率为25.7/100患者年,生物制剂初治患者为22.7/100患者年,经治患者>30/100患者年。
  • 处方者实践中的添加/换用率差异显著,最高十分位为53.8/100患者年,最低十分位为12.1/100患者年,相差超过四倍。

临床怎么用

  • 临床医生应了解RA患者启动生物制剂/JAKi的治疗顺序及单药治疗比例较高的情况。
  • 处方者间添加/换用率的显著差异提示需关注实践模式对治疗选择的影响。
  • 在开发预测治疗反应的生物标志物检测时,需考虑患者的治疗线数历史。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The opportunity for new biomarker-based tests to predict treatment response and the appropriate use of emerging rheumatoid arthritis (RA) therapies may depend on patients' treatment history. We examined RA treatment sequences and biologic/JAK inhibitor (JAKi) initiation overall and by line of therapy (LoT) to estimate the size of the eligible RA patient population in the United States for a new predictive treatment response test using a population-based RA inception cohort. METHODS: We used an augmented health plan claims database to create an inception cohort of patients with RA and estimated the rate of advanced treatment (biologic or JAKi) addition or switch. Results were stratified by advanced treatment-naïve versus treatment-experienced status and also described specific RA treatment sequences and combinations over time. RESULTS: Among 37,656 patients with RA, 59,557 new RA treatment initiations were identified. Most patients (85.2%) initiated biologics; the remainder initiated JAKi. Of these, 40.2% used biologics/JAKi as monotherapy. The overall biologic/JAKi addition/switch rate was 25.7 per 100 patient-years (py) (22.7/100 py in biologic-naïve patients and >30/100 py in treatment-experienced patients). Rates varied substantially between prescribers, with an observed add/switch rate in the practices of prescribers in the highest decile (53.8/100 py) more than four-fold greater than rates in the practice of prescribers in the lowest decile (12.1/100 py). CONCLUSION: These findings highlight the size and characteristics of the eligible RA population in the United States initiating a new RA biologic or JAKi treatment each year, thus providing valuable insights for stakeholders developing or marketing new RA therapies or biomarker-based diagnostic tests to predict future treatment response.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Curtis JR, Daigle S, Holladay EE, et al. Treatment Sequencing and Line of Therapy for Biologics and JAK Inhibitors in Patients With Rheumatoid Arthritis: Implications for Design and Uptake of New Drugs and Predictive Biomarker Diagnostics. Arthritis Care Res (Hoboken). 2026. PMID: 41693658. doi:10.1002/acr.80025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。